Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Despite intergroup clinical trials conducted in Europe and North America, outcomes for high risk patients with this disease have not significantly improved in the last several decades, and survival of metastatic or relapsed disease remains extremely poor. Accrual into new clinical trials is slow and difficult, so in vitro cell-line research and in vivo xenograft models present an attractive alternative for preclinical research for this cancer type. Currently, 30 commonly used human RMS cell lines exist, with differing origins, karyotypes, histologies, and methods of validation. Selecting an appropriate cell line for RMS research has important implications for outcomes. There are also potential pitfalls in using certain cell lines including contamination with murine stromal cells, cross-contamination between cell lines, discordance between the cell line and its associated original tumor, imposter cell lines, and nomenclature errors that result in the circulation of two or more presumed unique cell lines that are actually from the same origin. These pitfalls can be avoided by testing for species-specific isoenzymes, microarray analysis, assays for subtype-specific fusion products, and short tandem repeat analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma
Galili, N., Davis, R. J., Fredericks, W. J., Mukhopadhyay, S., Rauscher, F. J., Emanuel, B. S., Rovera, G., & Barr, F. G. (1993) · Nature Genetics · doi:10.1038/ng1193-230 · Cited by 892 · cited 2×
“For example, the “RH18” cell line can refer to the version not bearing the fusion gene (59), or the version bearing the fusion gene (60), which may have emerged from the original cell culture.”
BackgroundResultSelf-citationRearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma
Barr, F. G., Galili, N., Holick, J., Biegel, J. A., Rovera, G., & Emanuel, B. S. (1993) · Nature Genetics · doi:10.1038/ng0293-113 · Cited by 555 · cited 1×
“Though FOXO1 does localize to the 13q14 region, Northern blot studies of this line with a FOXO1 probe failed to show any evidence of a novel-sized transcript, thus suggesting that FOXO1 is not affected by these translocations (52).”
BackgroundSelf-citationTrends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005
Ognjanovic, S., Linabery, A. M., Charbonneau, B., & Ross, J. A. (2009) · Cancer · doi:10.1002/cncr.24465 · Cited by 497 · cited 10×
“RH41 (RH4) Lung metastasis 7-year-old female Yes t(2;13), TP53 mutation Yes”
BackgroundInfluentialThe pediatric preclinical testing program: Description of models and early testing results
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21078 · Cited by 480
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Khan, J. I., Simon, R., Bittner, M. L., Chen, Y., Leighton, S. B., Pohida, T. J., Smith, P. D., Jiang, Y. Y., Gooden, G. C., Trent, J. M., et al. (1998) · PubMed · Cited by 480
Short tandem repeat profiling provides an international reference standard for human cell lines
Masters, J. R., Thomson, J. A., Daly-Burns, B., Reid, Y. A., Dirks, W. G., Packer, P., Toji, L. H., Ohno, T., Tanabe, H., Arlett, C. F., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121616198 · Cited by 478 · cited 2×
“and low cost of this method are the strengths supporting its use as a standard of cell line authentication (87).”
MethodCoamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.
Khatib, Z. A., Matsushime, H., Valentine, M. B., Shapiro, D. N., Sherr, C. J., & Look, A. T. (1993) · PubMed · Cited by 389
Cultivation in vitro of cells derived from a human rhabdomyosarcoma
McAllister, R. M., Melnyk, J., Finklestein, J. Z., Adams, E. C., & Gardner, M. B. (1969) · Cancer · doi:10.1002/1097-0142(196909)24:3<520::aid-cncr2820240313>3.0.co;2-m · Cited by 323 · cited 1×
“RD RD was derived directly from biopsy specimens of a 7-year-old female with a pelvic RMS previously treated with cyclophosphamide and radiation and found to have refractory disease (27).”
MethodA specific chromosomal abnormality in rhabdomyosarcoma
Douglass, E. C., Valentine, M., Etcubanas, E., Parham, D., Webber, B. L., Houghton, P. J., & Green, A. A. (1987) · Cytogenetic and Genome Research · doi:10.1159/000132446 · Cited by 322 · cited 5×
“An alveolar RMS cell-line labeled RMS13 (39, 69) is thought by some investigators to be related to RH30, perhaps derived from the same patient tumor as RH30, but this is not clear.”
BackgroundInfluentialPPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C. E., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S., Duensing, S., Fletcher, C., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215634 · Cited by 276 · cited 6×
“It can now be obtained from Dr. Frederic Barr at the National Cancer Institute, Bethesda, MD, USA (personal communication, Dr. www.frontiersin.org July 2013 | Volume 3 | Article 183 | 5 Frederic Barr).”
InfluentialPappo, A. S., Anderson, J. R., Crist, W. M., Wharam, M. D., Breitfeld, P. P., Hawkins, D., Raney, R. B., Womer, R. B., Parham, D. M., Qualman, S. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3487 · Cited by 275
Shukla, N., Ameur, N., Yilmaz, I., Nafa, K., Lau, C.-Y., Marchetti, A., Borsu, L., Barr, F. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2056 · Cited by 232 · cited 1×
“This cell line was identified to have a V550L FGFR4 mutation by direct sequencing (46).”
BackgroundSelf-citationBetz, B. L., Strobeck, M. W., Reisman, D. N., Knudsen, E. S., & Weissman, B. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205706 · Cited by 212 · cited 1×
“In 2002, A204 cells were found to have a SMARCB1 (SNF5) mutation, consistent with its classification as a rhabdoid line (76).”
BackgroundFalse leukemia–lymphoma cell lines: an update on over 500 cell lines
Drexler, H. G., Dirks, W. G., Matsuo, Y., & MacLeod, R. A. F. (2003) · Leukemia · doi:10.1038/sj.leu.2402799 · Cited by 202
Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma.
Felix, C. A., Kappel, C. C., Mitsudomi, T., Nau, M. M., Tsokos, M., Crouch, G. D., Nisen, P. D., Winick, N. J., & Helman, L. J. (1992) · PubMed · Cited by 180
Weber-Hall, S. J., Anderson, J., McManus, A. P., Abe, S., Nojima, T., Pinkerton, R., Pritchard‐Jones, K., & SHIPLEY, J. M. (1996) · PubMed · Cited by 159
In Vivo Amplification of the PAX3-FKHR and PAX7-FKHR Fusion Genes in Alveolar Rhabdomyosarcoma
Barr, F. G., Nauta, L. E., Davis, R. J., Schäfer, B. W., Nycum, L. M., & Biegel, J. A. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.1.15 · Cited by 151 · cited 1×
“Unlike the typical PAX7FOXO1-containing tumor, this line does not show amplification of the PAX7-FOXO1 fusion gene (54).”
BackgroundSelf-citationCancer cell line identification by short tandem repeat profiling: power and limitations
Parson, W., Kirchebner, R., Mühlmann, R., Renner, K., Kofler, A., Schmidt, S., & Kofler, R. (2005) · The FASEB Journal · doi:10.1096/fj.04-3062fje · Cited by 129
MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas
Missiaglia, E., Shepherd, C. J., Patel, S. A., Thway, K., Pierron, G., Pritchard‐Jones, K., Renard, M., Sciot, R., Rao, P. K., Oberlin, O., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605684 · Cited by 128 · cited 1×
“RH41 was originally designated as alveolar by histology, and more recently has been shown to harbor the t(2;13) translocation (71).”
BackgroundVerification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines
Boonstra, J. J., van Marion, R., Beer, D. G., Lin, L., Chaves, P., Ribeiro, C., Pereira, A. D., Roque, L., Darnton, S. J., Altorki, N. K., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp499 · Cited by 127 · cited 1×
“In addition, three esophageal adenocarcinoma cell lines were recently found to derive from other tumors (86).”
Backgroundp53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines
Taylor, A. C., Shu, L., Danks, M. K., Poquette, C. A., Shetty, S., Thayer, M. J., Houghton, P. J., & Harris, L. C. (2000) · Medical and Pediatric Oncology · doi:10.1002/1096-911x(200008)35:2<96::aid-mpo2>3.0.co;2-z · Cited by 125 · cited 2×
“JR-1 cells have been shown to have mutation of the TP53 gene (26).”
BackgroundRAS signaling dysregulation in human embryonal Rhabdomyosarcoma
Martinelli, S., McDowell, H. P., Vigne, S. D., Kokai, G. K., Uccini, S., Tartaglia, M., & Dominici, C. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20702 · Cited by 119 · cited 2×
“CCA cells harbor a Q61L mutation in KRAS (21).”
BackgroundMolecular Characterization of the Pediatric Preclinical Testing Panel
Neale, G., Su, X., Morton, C. L., Phelps, D., Gorlick, R., Lock, R. B., Reynolds, C. P., Maris, J. M., Friedman, H. S., Dome, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5090 · Cited by 118 · cited 4×
“The Pediatric Preclinical Testing Panel (PPTP) is an initiative formed by the National Cancer Institute, working to further characterize and validate available cell lines in multiple kinds of pediatric cancer, including RMS so that preclinical evaluations of new chemotherapeutic agents can be tested (4).”
BackgroundMethodResultInfluentialCD133 Positive Embryonal Rhabdomyosarcoma Stem-Like Cell Population Is Enriched in Rhabdospheres
Walter, D., Satheesha, S., Albrecht, P., Bornhauser, B. C., D’Alessandro, V., Oesch, S., Rehrauer, H., Leuschner, I., Kościelniak, E., Gengler, C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019506 · Cited by 118 · cited 1×
“recently described a method of culturing rhabdospheres in suspension (79).”
MethodMyogenesis and Rhabdomyosarcoma
Saab, R. H., Spunt, S. L., & Skapek, S. X. (2011) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-380916-2.00007-3 · Cited by 117 · cited 8×
“der(3)t(1;3)(q12;p12–14), 16q-, 17q+, and”
BackgroundInfluentialCytogenetic studies in subgroups of rhabdomyosarcoma
Whang‐Peng, J., Knutsen, T., Theil, K. S., Horowitz, M. E., & Triche, T. J. (1992) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870050405 · Cited by 109 · cited 2×
“TC212 TC212 has an alveolar histology (based on histology of the tumor specimens) and was derived from the bone marrow metastasis of a 16-year-old male who relapsed 5 months after multi-agent chemotherapy and radiation (51).”
BackgroundWhiteford, C. C., Bilke, S., Greer, B. T., Chen, Q., Braunschweig, T. A., Cenacchi, N., Wei, J. S., Smith, M. A., Houghton, P., Morton, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-0610 · Cited by 108 · cited 3×
“These analyses were compared to cDNA of primary tumors and all clustered appropriately by tumor type except RH1 and RH6 (37).”
MethodInfluentialMissiaglia, E., Selfe, J., Hamdi, M., Williamson, D., Schaaf, G., Fang, C., Koster, J., Summersgill, B., Messahel, B., Versteeg, R., et al. (2009) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20655 · Cited by 108
Dias, P., Parham, D. M., Shapiro, D. N., Tapscott, S. J., & Houghton, P. J. (1992) · PubMed · Cited by 107
Kang, M. H., Smith, M. A., Morton, C. L., Keshelava, N., Houghton, P. J., & Reynolds, C. P. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22801 · Cited by 102
Miyachi, M., Kakazu, N., Yagyu, S., Katsumi, Y., Tsubai-Shimizu, S., Kikuchi, K., Tsuchiya, K., Iehara, T., & Hosoi, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2955 · Cited by 100
PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma
Taniguchi, E., Nishijo, K., McCleish, A. T., Michalek, J. E., Grayson, M. H., Infante, A. J., Abboud, H. E., LeGallo, R. D., Qualman, S. J., Rubin, B. P., et al. (2008) · Oncogene · doi:10.1038/onc.2008.255 · Cited by 100 · cited 2×
“RH5 has an alveolar histology and has been cited in a study of the role of PDGFR-A (56).”
BackgroundCharacterization of cell lines derived from xenografts of childhood rhabdomyosarcoma.
Hazelton, B. J., Houghton, J. A., Parham, D. M., Douglass, E. C., Torrance, P. M., Holt, H., & Houghton, P. J. (1987) · PubMed · Cited by 90
Crose, L. E. S., Etheridge, K. T., Chen, C., Belyea, B., Talbot, L. J., Bentley, R. C., & Linardic, C. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3063 · Cited by 89 · cited 1×
“In addition, although RH3 and RH28 appear genetically identical by fusion breakpoint and STR analysis (64, 81), it is not clear whether the two cell lines were derived from the same tumor from the same patient on the same date.”
BackgroundSelf-citationDeCristofaro, M. F., Betz, B. L., Wang, W., & Weissman, B. E. (1999) · Oncogene · doi:10.1038/sj.onc.1203168 · Cited by 87 · cited 5×
“This cell line was originally obtained from the laboratory of Dr. Tim Triche of Children’s Hospital Los Angeles (CHLA) (43, 53).”
BackgroundInfluentialThompson, J., George, E. O., Poquette, C. A., Cheshire, P. J., Richmond, L. B., de Graaf, S. S. N., Ma, M., Stewart, C. F., & Houghton, P. J. (1999) · PubMed · Cited by 86
Linardic, C. M., Naini, S., Herndon, J. E., Kesserwan, C., Qualman, S. J., & Counter, C. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3210 · Cited by 73
Self-citationSK‐NEP‐1 and Rh1 are Ewing family tumor lines
Smith, M. A., Morton, C. L., Phelps, D. A., Girtman, K., Neale, G. A. M., & Houghton, P. J. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21099 · Cited by 70 · cited 1×
“RH1 was later verified to express the EWS-FLI1 fusion characteristic of the Ewing family of tumors (78).”
BackgroundGenomic characterization of explant tumorgraft models derived from fresh patient tumor tissue
Monsma, D. J., Monks, N. R., Cherba, D., Dylewski, D., Eugster, E., Jahn, H., Srikanth, S., Scott, S. B., Richardson, P. J., Everts, R. E., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-125 · Cited by 67 · cited 1×
“A recent study describes an approach to develop xenografts directly from patient tumors, then test them for genomic similarities (80).”
BackgroundGarvin, A. J., Stanley, W. S., Bennett, D. D., Sullivan, J. L., & Sens, D. A. (1986) · PubMed Central · Cited by 66
Schaaf, G., Hamdi, M., Zwijnenburg, D. A., Lakeman, A., Geerts, D., Versteeg, R., & Kool, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2532 · Cited by 65
Amplification of MDM2 Inhibits MyoD-Mediated Myogenesis
Fiddler, T. A., Smith, L., Tapscott, S. J., & Thayer, M. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.5048 · Cited by 63 · cited 2×
“TP53 pathway gene analysis showed no mutation of the TP53 gene, but did show upregulation of MDM2 (31).”
BackgroundCinatl, J. J., Činátl, J., Michaelis, M., Kabíčková, H., Kotchetkov, R., Vogel, J., Doerr, H. W., Klingebiel, T., & Driever, P. H. (2003) · PubMed · Cited by 61
Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques
Martínez‐Ramírez, Á., Rodríguez, S., Meléndez, B., Martínez–Delgado, B., Urioste, M., Cigudosa, J. C., & Benitez, J. J. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00670-2 · Cited by 60
Hu, K., Lee, C., Qiu, D., Fotovati, A., Davies, A., Abu‐Ali, S., Wai, D., Lawlor, E. R., Triche, T. J., Pallen, C. J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0365 · Cited by 53 · cited 3×
“Tim Triche of Children’s Hospital Los Angeles (CHLA) (43, 53).”
BackgroundPAX3-FOXO1 Induces Cannabinoid Receptor 1 to Enhance Cell Invasion and Metastasis
Marshall, A. D., Lagutina, I. V., & Grosveld, G. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0924 · Cited by 52 · cited 1×
“More recently, other studies do mention that this cell line expresses myogenic markers (38).”
BackgroundGrowth and characterization of childhood rhabdomyosarcomas as xenografts.
Houghton, J. A., Houghton, P. J., & Webber, B. L. (1982) · PubMed · Cited by 46
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma
Sokolowski, E. I., Turina, C. B., Kikuchi, K., Langenau, D. M., & Keller, C. (2013) · Oncogene · doi:10.1038/onc.2013.129 · Cited by 45
Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice.
Houghton, J. A., Houghton, P. J., & Green, A. A. (1982) · PubMed · Cited by 40
Chadalapaka, G., Jutooru, I., Sreevalsan, S., Pathi, S. S., Kim, K., Chen, C., Crose, L. E. S., Linardic, C. M., & Safe, S. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.27730 · Cited by 39 · cited 2×
“After treatment, RH30 cells showed decreased growth, decreased cell migration, and decreased expression of the PAX3-FOXO1 fusion protein (33).”
BackgroundMethodSelf-citationHoughton, J. A., Cook, R. L., Lutz, P., & Houghton, P. J. (1984) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(84)90170-6 · Cited by 35
RMZ: A new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin
Nanni, P., Schiaffino, S., Giovanni, C. D., Nicoletti, G., Prodi, G., Re, B. D., Eusebi, V., Ceccarelli, C., Saggin, L., & Lollini, P. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.273 · Cited by 35
Structural Analysis of PAX3 Genomic Rearrangements in Alveolar Rhabdomyosarcoma
Barr, F. G., Nauta, L. E., & Hollows, J. C. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(97)00287-2 · Cited by 32 · cited 2×
“In addition, although RH3 and RH28 appear genetically identical by fusion breakpoint and STR analysis (64, 81), it is not clear whether the two cell lines were derived from the same tumor from the same patient on the same date.”
BackgroundSelf-citationFibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma
Ito, H., Duxbury, M. S., Benoit, E., Farivar, R. S., Gardner-Thorpe, J., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.070 · Cited by 29 · cited 6×
“It can now be obtained from Dr. Frederic Barr at the National Cancer Institute, Bethesda, MD, USA (personal communication, Dr. www.frontiersin.org July 2013 | Volume 3 | Article 183 | 5 Frederic Barr).”
InfluentialFrascella, E., Lenzini, E., Schäfer, B. W., Brečević, L., Dorigo, E., Toffolatti, L., Nanni, P., Giovanni, C. D., & Rosolen, A. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(00)00258-2 · Cited by 23 · cited 2×
“Both the PAX7-FOXO1 fusion gene and MYCN were found amplified (65, 72).”
BackgroundShapiro, D. N., Houghton, P. J., Hazelton, B. J., Germain, G. S., Murti, K. G., Rahman, A., & Houghton, J. A. (1990) · PubMed · Cited by 20
Morton, C. L., & Potter, P. M. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37689-x · Cited by 18 · cited 4×
“In 1998, RH1 was noted to lack expression of the myogenic markers myogenin, MyoD, and desmin (23).”
BackgroundInfluentialTakaoka, E., Sonobe, H., Akimaru, K., Sakamoto, S., Shuin, T., Daibata, M., Taguchi, T., & Tominaga, A. (2012) · PubMed · Cited by 17
Authentication of Cancer Cell Lines by DNA Fingerprinting
Dirks, W. G., & Drexler, H. G. (2003) · Cancer Cell Culture · doi:10.1385/1-59259-406-9:43 · Cited by 16
Telomerase Activity in Cell Lines of Pediatric Soft Tissue Sarcomas
Kleideiter, E., Schwab, M. G., Friedrich, U. A., Kościelniak, E., Schäfer, B. W., & Klotz, U. E. (2003) · Pediatric Research · doi:10.1203/01.pdr.0000086901.29111.2a · Cited by 16 · cited 1×
“+der(8)t(8;?)(p23;?), +M Upregulation of”
Nicoletti, G., Giovanni, C. D., Landuzzi, L., Simone, G., Rocchi, P., Nanni, P., & Lollini, P. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.107 · Cited by 14 · cited 1×
“RMZ-RC2 cells treated in culture with 2–5 Gy of radiation show dose-sensitive increases in the expression of myosin and the percentage of multinucleated cells, both markers of differentiation (74).”
BackgroundEMBRYONAL RHABDOMYOSARCOMA IN NUDE MICE AND IN VITRO
Motoyama, T., Watanabe, H., & Yamamoto, T. (1986) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1986.tb02821.x · Cited by 7
In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma
Rodeberg, D. A., Erskine, C. L., & Celis, E. (2007) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2007.03.041 · Cited by 7 · cited 1×
“Other studies have presumed RMS13 and RH30 to be independent entities (70).”
BackgroundBerner (1996) · doi:10.1002/(sici)1098-2264(199612)17:4
Cited by
Yu, P. Y., Gardner, H. L., Roberts, R., Cam, H., Hariharan, S., Ren, L., LeBlanc, A. K., Xiao, H., Lin, J., Guttridge, D. C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181885 · Cited by 17
Metadata
- Authors
- Hinson, A. R. P., Jones, R., Crose, L. E. S., Belyea, B. C., Barr, F. G., & Linardic, C. M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 183-183
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2076819367
- Cited by
- 192
- References
- 64
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.